Lack of Efficacy of Low‐Dose Cyclobenzaprine on Electromyographic Activity Related to Sleep Bruxism: A Randomized Crossover Double‐Blind Placebo‐Controlled Clinical Trial
Authors:
- Matheus Herreira‐FerreiraMHMatheus Herreira‐Ferreira
- Cibele Dal FabbroCFCibele Dal Fabbro
- Gilles J. LavigneGLGilles J. Lavigne
- Juliana Stuginski‐BarbosaJSJuliana Stuginski‐Barbosa
- Peter SvenssonPSPeter Svensson
- Paulo César Rodrigues ContiPCPaulo César Rodrigues Conti
- Leonardo Rigoldi BonjardimLBLeonardo Rigoldi Bonjardim
Open Access
- 29 August 2026
- journal article
- research article
- Published by Wiley in Journal of Sleep Research
- p. e70446
Abstract
Sleep bruxism (SB) is a motor activity characterized by repetitive masticatory muscle contractions during sleep, commonly associated with tooth damage and jaw pain or headache. Pharmacological management strategies targeting its central nervous system‐related mechanisms remain limited. This study aimed to evaluate whether a low dose of a central muscle relaxant, cyclobenzaprine, reduces SB‐related muscle activity, maximum voluntary bite force and self‐reported bruxism awareness. A randomized, double‐blind, placebo‐controlled, crossover clinical trial was conducted. Twenty participants underwent baseline SB motor activity recordings followed by two intervention phases consisting of 5 mg of cyclobenzaprine or placebo for three consecutive nights. Masticatory muscle activity during sleep was quantified using portable surface electromyography. Maximum voluntary bite force was measured using a bite force‐recording device. Self‐reported outcomes related to SB and secondary effects (e.g., dry mouth) were collected each morning. Comparison of cyclobenzaprine to placebo and baseline nights failed to show a difference in mean frequency of masticatory muscle activity during sleep and maximum voluntary bite force. No self‐reported differences were observed for SB awareness. Few secondary effects were identified between cyclobenzaprine use and placebo; a significant increase in perception of tolerable dry mouth upon awakening ( p = 0.034) and a marginally statistically significant reduction in the perceived leg movements during sleep ( p = 0.046). In conclusion, low‐dose cyclobenzaprine was not effective in modifying SB–related muscle activity or masticatory muscle force, suggesting limited clinical utility for SB. Future studies using higher doses of cyclobenzaprine are warranted before ruling out its clinical utility, within a safety profile.Keywords
This publication has 25 references indexed in Scilit:
- Managements of sleep bruxism in adult: A systematic reviewJapanese Dental Science Review, 2022
- Multitargeting the sleep-pain interaction with pharmacological approaches: A narrative review with suggestions on new avenues of investigationSleep Medicine Reviews, 2021
- Clonidine Has a Paradoxical Effect on Cyclic Arousal and Sleep Bruxism during NREM SleepSLEEP, 2010
- The Effect of 2 Sympatholytic Medications—Propranolol and Clonidine—On Sleep Bruxism: Experimental Randomized Controlled StudiesSLEEP, 2006
- Treatment of fibromyalgia with cyclobenzaprine: A meta‐analysisArthritis Care & Research, 2004
- Cyclobenzaprine and Back PainArchives of internal medicine (1960), 2001
- The Effect of Four-Week Administration of Amitriptyline on Sleep Bruxism. A Double-Blind Crossover Clinical StudyCranio®, 2001
- A Randomized Double-blind Clinical Trial of the Effect of Amitriptyline on Nocturnal Masseteric Motor Activity (Sleep Bruxism)Cranio®, 1997
- The effect of the catecholamine precursor L‐Dopa on sleep bruxism: A controlled clinical trialMovement Disorders, 1997
- Restless Legs Syndrome and Sleep Bruxism: Prevalence and Association Among CanadiansSLEEP, 1994